Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01107249 · ClinicalTrials.gov registry record · Phase 2

A Trial of Esophageal and Gastric Stenting for Leak or Perforation

A Phase 2 study of Esophageal or Gastric Perforations and Esophageal or Gastric Leaks, sponsored by The Methodist Hospital Research Institute.

Completed
Registry status
Phase 2
Development phase
10
Enrollment target
1
Study location

NCT01107249 is a Phase 2 study of Esophageal or Gastric Perforations and Esophageal or Gastric Leaks that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01107249, a Phase 2 study of Esophageal or Gastric Perforations and Esophageal or Gastric Leaks, has completed, sponsored by The Methodist Hospital Research Institute.

COMPLETED
Registry status
Phase 2
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Long term follow-up of patients treated for esophageal fistulas with a newer occlusive self-expanding covered metal stents compared to traditional stents.

Interventions

  • DEVICE Boston Scientific Ultraflex or Wallstent stents

Study Locations (1)

Texas

  • The Methodist Hospital - Houston

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2010-05
Est. Completion 2014-10
Phase Phase 2

What the Registry Record Tells You About NCT01107249

The ClinicalTrials.gov registry entry for NCT01107249 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Esophageal or Gastric Perforations appearing as the primary indexed condition, and to 1 intervention - of which Boston Scientific Ultraflex or Wallstent stents is the first listed.

NCT01107249 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01107249 about?

NCT01107249 is a clinical study titled "A Trial of Esophageal and Gastric Stenting for Leak or Perforation". Long term follow-up of patients treated for esophageal fistulas with a newer occlusive self-expanding covered metal stents compared to traditional stents.

What is the current status of trial NCT01107249?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-05. Estimated completion is 2014-10.

What conditions does trial NCT01107249 study?

This clinical trial studies the following conditions: Esophageal or Gastric Perforations, Esophageal or Gastric Leaks.

What interventions are being tested in trial NCT01107249?

The interventions under investigation include: Boston Scientific Ultraflex or Wallstent stents (DEVICE).

Who is sponsoring clinical trial NCT01107249?

This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01107249 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.